Clinical trials and field studies have demonstrated that MenAfriVac is highly effective. It provides long-lasting immunity and has been shown to reduce carriage of the meningococcal bacteria, thereby decreasing transmission. Introduction of the vaccine has led to a dramatic decline in cases of serogroup A meningitis in vaccinated populations. According to WHO reports, the implementation of MenAfriVac has nearly eliminated serogroup A meningitis in the regions where it has been administered.
